Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00134147 · ClinicalTrials.gov registry record · Phase 3
A Clinical Trial Assessing the Impact of the Availability of Inhaled Insulin on Glucose Control
A Phase 3 study of Diabetes Mellitus, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,100
- Enrollment target
- 20
- Study locations
NCT00134147: Completed Phase 3 study of Diabetes Mellitus, sponsored by Pfizer.
NCT00134147 is a Phase 3 study of Diabetes Mellitus that has completed, run by Pfizer. The registered enrollment target is 1,100 participants, below the 1,862-participant average among 208 other Diabetes Mellitus trials with a reported enrollment target (41% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00134147, a Phase 3 study of Diabetes Mellitus, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,100 participants
- Enrollment target
- 20
- Study locations
Study Summary
To assess the impact on glucose control by inhaled insulin in patients with type 2 diabetes who are not well controlled on 2 or more oral anti-diabetic agents
Conditions Studied
Interventions
- DRUG Inhaled Insulin
Study Locations (20)
Florida
- Pfizer Investigational Site - Jacksonville
- Pfizer Investigational Site - Jacksonville
- Pfizer Investigational Site - Miami
North Carolina
- Pfizer Investigational Site - Charlotte
- Pfizer Investigational Site - Charlotte
- Pfizer Investigational Site - Raleigh
California
- Pfizer Investigational Site - La Jolla
- Pfizer Investigational Site - San Diego
Texas
- Pfizer Investigational Site - San Antonio
- Pfizer Investigational Site - San Antonio
Alberta
- Pfizer Investigational Site - Calgary
- Pfizer Investigational Site - Edmonton
District of Columbia
- Pfizer Investigational Site - Washington D.C.
Georgia
- Pfizer Investigational Site - Columbus
Kansas
- Pfizer Investigational Site - Overland Park
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,100 participants |
| Start Date | 2005-04 |
| Est. Completion | 2007-05 |
| Phase | Phase 3 |
What the finished NCT00134147 record still lists
NCT00134147 is an interventional study that assigns participants to a tested intervention. Its 1,100 participants enrollment target places it among the larger protocols in the corpus, below the 1,862-participant average among 208 other Diabetes Mellitus trials with a reported enrollment target (41% lower).
The record links to 1 condition, with Diabetes Mellitus appearing as the primary indexed condition, and to 1 intervention - of which Inhaled Insulin is the first listed.
NCT00134147 names 20 study sites across 13 states, led by Florida, North Carolina, California.
Frequently Asked Questions
What is clinical trial NCT00134147 about?
NCT00134147 is a clinical study titled "A Clinical Trial Assessing the Impact of the Availability of Inhaled Insulin on Glucose Control". To assess the impact on glucose control by inhaled insulin in patients with type 2 diabetes who are not well controlled on 2 or more oral anti-diabetic agents
What is the current status of trial NCT00134147?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,100 participants. The study started on 2005-04. Estimated completion is 2007-05.
What conditions does trial NCT00134147 study?
This clinical trial studies the following conditions: Diabetes Mellitus.
What interventions are being tested in trial NCT00134147?
The interventions under investigation include: Inhaled Insulin (DRUG).
Who is sponsoring clinical trial NCT00134147?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00134147 being conducted?
This trial has 20 study locations across California, District of Columbia, Florida, Georgia, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00134147's enrollment target sits among peer trials
1,100 27th of 208 higher than 182 of 208 other Diabetes Mellitus trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetes Mellitus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate ENERGI-F703 GEL in Diabetic Foot Ulcer
RECRUITING · Phase 3
-
Dapagliflozin in Patients With Atrial Fibrillation (DAPA-AF)
RECRUITING · Phase 3
-
Effect of a Decision Aid About Statin Use in Patients With Type 2 Diabetes Mellitus
COMPLETED · Phase 3
-
Compare Blood Sugar Level Between Lantus in the Morning and Other Insulins in Type 1 Diabetes Adolescents
COMPLETED · Phase 3
-
Treatment of Peripheral Neuropathy in Patients With Diabetes
COMPLETED · Phase 3
-
Action to Control Cardiovascular Risk in Diabetes (ACCORD)
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00710112 · 1,100 participants
Genetic Variants and Susceptibility to Diseases of Prematurity in Very Low Birth-Weight Infants
- NCT02688517 · 1,100 participants
Targeted Genomic Analysis of Blood and Tissue Samples From Patients With Cancer
- NCT04743765 · 1,100 participants · NA
HIP Fracture Accelerated Surgical TreaTment And Care tracK 2 Trial
- NCT05638581 · 1,100 participants · Phase 3
Trauma Resuscitation With Low-Titer Group O Whole Blood or Products
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia